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Abstract- Capecitabine, an effective anticancer drug in colorectal cancer chemotherapy, may create adverse 
side effects on healthy tissues. In the present study, we first induced colon adenocarcinoma with 
azoxymethane, a carcinogen agent, and then investigated the potentiality of polyamidoamine (PAMAM) 
dendrimer to improve capecitabine therapeutic index and decrease its adverse side effects on healthy tissues 
like liver and bone marrow. Other variables such as nanoparticle concentrations have also been investigated. 
Drug loading concentration (DLC) and encapsulation efficiency (EE) were calculated for 
capecitabine/dendrimer complex. Experimental results showed an increase in DLC percentage resulted from 
elevated capecitabine/dendrimer ratio. Capecitabine/dendrimer complex could reduce tumor size and adverse 
side effects in comparison with free capecitabine form. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(8):485-493. 
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Introduction 
 
Colorectal cancer is the third most common 
malignancy in the world and is the fourth most 
commonly diagnosed cancer and the second leading 
cause of cancer related death in the United States (1). 
Development of colorectal cancer is a process 
sequentially acquiring a number of genetic changes in 
normal epithelium, which enables precancerous cells to 
change into an adenomatous polyp and progress into an 
invasive tumor (2,3). Although the development of 
colorectal cancer is usually sporadic, risk factors 
include increasing age, male gender; diseases such as 
diabetes, inflammatory bowel syndrome and 
environmental factors including high fat/low fiber 
diets, excessive alcohol consumption, smoking, obesity 
and sedentary lifestyle are closely connected with the 
disease (4-10). Surgical resection is the primary 
modality for the colorectal cancer treatment, though 
preoperative (neoadjuvant) and postoperative 
(adjuvant) chemotherapies have important roles to 
increase survival (11,12). Chemotherapy drugs in 
colorectal cancer include oxaliplatin, irinotecan, 
Avastin® (bevacizumab), 5-fluorouracil (5-Fu) and 
Xeloda® (capecitabine) (13-17). Capecitabine, an oral 
chemotherapeutic prodrug for breast and colorectal 
cancer, enzymatically converts to 5-Fu in the tumor, 
inhibits DNA synthesis and slows the growth of 
tumoral tissues (18,19).  
Although chemotherapeutic agents can reduce 
tumor size and cancer remission and have high 
potential to destroy cancer cells, they are not organ 
specific and can damage proliferative cells (20). 
Sensitive cells to chemotherapeutic agents include 
blood cells, hair cells and the cells lining the intestine 
which are prone to commonly induced side effects such 
as myelosuppression, diarrhea, alopecia, and liver 
malfunction. On the other hand, whole body drug 
distribution necessitates the use of high doses and 
repeated frequency of their administration. 
In the last decade, specifically targeted drug delivery 
has been the main objective of the cancer treatment to 
decrease chemotherapeutic side effects, doses, and 
frequency of administration. Extensive researches have 
also been done to reach this aim among which different 
nanocarriers use for targeted drug delivery is one of the 
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striking means (21-25). Polymeric systems are among 
most widely used drug carrier delivery protocols. One of 
the most common applications of conjugated polymer-
drug is anti-cancer therapeutic delivery (26-28). 
Chemotherapeutic conjugation with polymeric carriers 
has the capacity to improve therapeutic index by 
enhanced drug accumulation at the tumor with fewer 
side effects in other organs (29).  
One of the most widely studied properties of 
polymeric drug delivery is the enhanced permeability 
and retention (EPR) (30-33) effect. The EPR effect 
describes the propensity of macromolecules to 
accumulate in solid tumors (34). Because of rapid 
angiogenesis associated with solid tumor formation, 
tumors have dense and leaky vasculature which allows 
easy permeation of molecules. Microvasculature and 
lack of lymphatic drainage lead to retention and 
accumulation of the delivered compounds in a tumor. In 
EPR targeting, the therapeutic agent is locally released 
and taken up by tumor cells to achieve its target. Thus, 
passive targeting by the EPR effect allows drug 
accumulation at the tumor site and improves therapeutic 
index compared to the free drug.  
The ability of polymers to serve as backbones for 
drug conjugation, targeting moieties and imaging agents 
make them powerful multifunctional delivery system 
(35). Any degradation of the carrier or premature release 
of the free drug before reaching to the desired location 
defeats the carrier purpose and reduces targeting 
efficacy and finally increases side effects. For this 
reason, a stable system is required for any 
macromolecular carrier system for targeted drug 
delivery. 
In the search for an ideal carrier system, dendrimers 
may have significant potentials. Dendritic polymers or 
dendrimers have been proposed as one type of carrier in 
targeted drug delivery (36). The unique characteristics 
of dendrimers such as uniform and controlled size and 
modifiable surface group functionality make these 
molecules appealing for biomedical applications (37). 
The ability to functionalize their terminal groups with 
various targeting, therapeutic and imaging agents in a 
specific and controllable manner provides the potential 
to use the dendrimers as suitable carriers for targeted 
drug delivery. The utility of the internal void volume of 
dendrimers to encapsulate hydrophobic guest molecules 
and drugs has been demonstrated by several research 
groups (37). Aqueous solubility, biocompatibility, and 
availability, however, lead to limited drug delivery 
investigations to find very few classes of dendrimers 
(38,39). The PAMAM dendrimers, which fulfill most 
requirements for use in in vivo applications, are 
extensively being considered for medical applications 
and are under vast investigations for their use as carriers 
in gene transfection, MRI contrast agents and drug 
delivery applications (36,40,41). The internal tertiary 
amines of PAMAM dendrimers are available for acid–
base interactions and hydrogen bonding as well as other 
non-covalent interactions. Encapsulated guest molecules 
make the polymers effective agents for solubilizing 
hydrophobic drugs. PAMAM dendrimers have been 
shown to exhibit minimum cytotoxicity up to 
generation4 (42,43). The potential of PAMAM 
dendrimers as oral drug delivery carriers was first 
reported in 2000 by Wiwattanapatapee (44). Colorectal 
cancer incidence is increasing over the world and also in 
Iran. On the other hand, cancer treatment is expensive 
and rather difficult to follow. In addition, whole body 
distribution of chemotherapeutics requires frequent 
doses which accompanied by disparate adverse effects 
on healthy tissues. Conceivably, searching new methods 
are inevitable. In this study, we investigate PAMAM 
dendrimer application with capecitabine, a 
chemotherapeutic agent, for target drug delivery in 
neoadjuvant colorectal chemotherapy and compare the 
effects of free and conjugated capecitabine form on 
tumor size and blood cell lines abnormalities.  
 
Materials and Methods 
 
1.1. Materials 
PAMAM-G4-NH2 (molecular weight=14,215 g/mol, 
64 amine end groups), azoxymethane and capecitabine, 
were purchased from Aldrich chemical company. 
 
1.2. Animals 
Male NMRI inbred albino mice (20-25 g) were kept 
in a temperature controlled environment on a 12:12 
light/dark cycle with free access to food and water. The 
procedures were in accordance with the guidelines for 
the care and use of laboratory animals of Tehran 
University of Medical Sciences. 
 
1.3. Study design 
According to the study protocol, fifty male NMRI 
inbred albino mice were equally divided into five groups 
of 10 as per follows (i) vehicle control, animals in this 
group, received normal saline (0.5 ml, i.p, once a week 
for 6 weeks), (ii) positive control, received 
azoxymethane (45) (10 mg/kg i.p, once a week for 6 
weeks) for cancer induction, (iii) capecitabine, animals 
first received azoxymethane like group 2, and then 20 
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weeks after the last azoxymethane injection, they 
received capecitabine (700 mg/kg/day) through oral 
gavages for 3 cycles (each cycle include 1 week drug 
administration than 1 week rest), (iv) PAMAM 
dendrimers, animals first received azoxymethane for 
cancer induction and then 20 weeks after the last 
azoxymethane injection, they received PAMAM 
dendrimer through oral gavages (244 mg/ml) twice a 
day for 3 cycle, (v) capecitabine-PAMAM dendrimer 
complex, animals first received azoxymethane for 
cancer induction and then 20 weeks after the last 
azoxymethane dose, they received capecitabine-
PAMAM dendrimer complex for 3 cycle. The 
examination finished on week 32. 
 
1.4. Capecitabine calibration curve 
An excess of capecitabine (10 mg) dissolved in 10 
ml deionized water. The mixture then stirred with a 
shaker to make the stock solutions (1-5 g/ml). Prepared 
solutions kept in the amber colored bottle to avoid 
dendrimer and capecitabine degeneration. 
Capecitabine calibration curve at different 
concentration (1-5 g/ml) were obtained using specific 
absorbance peak at 240 nm. Maximum absorbance of 
PAMAM dendrimer was also determined. 
 
1.5. Capecitabine dendrimer encapsulation 
Capecitabine dissolved in deionized water (5 
g/ml) .The capecitabine/PAMAM dendrimer ratio of 
5:1, 5:2, 5:3, 5:4 and 5:5 obtained from several trials. 
The mixture stirred in a dark environment at 37ºC for 
24 hours with a shaker. After equilibration prepared 
suspensions centrifuged at 3000 rpm for 10 minutes. 
One ml of each centrifuged solution was taken to 
estimate the amount of dendrimer incorporated drug 
using Uv-vis spectrometer. Maximum absorbance and 
calibration curve of capecitabine at different 
concentrations (1-5 µg/ml) were determined using 
specific absorbance peak at 240 nm. 
 
1.6. Drug loading concentration (DLC) and 
encapsulation efficiency (EE) 
Encapsulation efficiency is defined as the 
percentage of capecitabine loading content that can be 
entrapped into PAMAM dendrimer. 
DLC and EE were calculated from the following 
equations: 
Drug loading concentration (%) =  
 
ܦݎݑ݃	ݓ݄݁݅݃ݐ	݅݊	݊ܽ݊݋݌ܽݎݐ݈݅ܿ	
ܰܽ݊݋݌ܽݎݐ݈݅ܿ݁ݏ	ݓ݄݁݅݃ݐ ∗ 100 
 
Encapsulation Efficiency (%) =  
 
ܶ݋ݐ݈ܽ	ܿܽ݌݁ܿ݅ݐܾܽ݅݊݁	– ݂ݎ݁݁	ܿܽ݌݁ܿ݅ݐܾܽ݅݊݁		
ܶ݋ݐ݈ܽ	ܿܽ݌݁ܿ݅ݐܾܽ݅݊݁	 ∗ 100 
 
According to Encapsulation Efficiency and Drug 
Loading Concentration percentage, the appropriated 
ratio of capecitabine-PAMAM dendrimer was selected. 
 
1.7. Laboratory tests 
At the end of the study, animals were anesthetized 
with ketamine (50 mg/kg, i.p). The abdominal cavity 
was opened with a midline incision. Thoracic cavity 
was also opened for cardiac blood sampling. One ml of 
each sample centrifuged for 5 min in 7000 rpm for 
serum collections. Serological tests including alanine 
aminotransferase (ALT) and aspartate aminotransferase 
(AST) were then measured. Red blood cell (RBC) and 
platelet (PLT) were also counted using extra 1 ml 
blood sample. 
 
1.8. Histological assay 
Colorectal tumoral and adjacent non-tumoral 
mucosal tissues were excised from the collected 
specimens and fixed in 10% formaldehyde, passaged 
and embedded in paraffin. Paraffin blocks were then 
sectioned into 3-5 m thickness for H and E staining. 
Nine serial sections were prepared from each case for 
hematoxylin and eosin (H and E) staining. 
 
1.9. Statistical analysis 
Results were expressed as meansSEM. Analysis of 
variance (ANOVA) and post hoc Tukey test was used 
for comparison between groups. Fisher’s exact 
probability test was used to show different tumor 
incidences expressed as a percentage of animals with 
colon adenocarcinoma. Ratio comparison was 
determined by chi-square test. P-values below 0.05 
were considered statistically significant. 
 
Results 
 
2.1. Determined encapsulation efficiency (EE) and 
drug loading concentration (DLC) 
The capecitabine-PAMAM dendrimer ratio used 
throughout this study was 5:1, 5:2, 5:3, 5:4 and 5:5 that 
obtained from several trials (Table 1). 
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Table 1. Capecitabine nanoparticle ratio
Formulation Capecitabine (µg/ml) 
PAMAM dendrimer 
(µg/ml) 
F1 5.0 1.0 
F2 5.0 2.0 
F3 5.0 3.0 
F4 5.0 4.0 
F5 5.0 5.0 
 
 
The EE and DLC of capecitabine nanoparticles were 
measured using spectrophotometry method (Table 2). 
Capecitabine standard curve was obtained by plotting 
the concentration from 1 μg/ml to 5 μg/ml at 240 nm 
(Figure 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Capecitabine Standard Calibration Curve using 
spectrophotometer 
 
The effects of capecitabine-dendrimer ratio on 
encapsulation efficiency and drug loading concentration 
were demonstrated. Increasing PAMAM dendrimer 
concentration during encapsulation process provoking 
more protonated form while boosting surface charge 
leading to the stronger electrostatic interaction between 
capecitabine and PAMAM dendrimer. Encapsulation 
efficiency of capecitabine decrease with higher PAMAM 
dendrimer concentration (Table 2). Capecitabine drug 
loading concentration was also increased when PAMAM 
dendrimer concentration boosted (Table 2). Reversed 
correlation was seen between encapsulation efficiency 
and capecitabine loading concentration. 
According to DLC and EE percentage, the 
capecitabine-PAMAM dendrimer ratio selected in this 
study was 5 to 1. With increasing capecitabine-PAMAM 
dendrimer ratio, EE percentage decreased. In this study, 
we selected 5 to 1 ratio capecitabine-PAMAM dendrimer 
because in this ratio EE percentage is higher than others. 
According to EE and DLC percentage, we can to 
determined how much of capecitabine loaded in 
capecitabine-PAMAM dendrimer complex. According to 
this data, the amount of PAMAM dendrimer was required 
for formation complex containing 700 mg/ml of 
capecitabine was determined. 
 
Table 2. Encapsulation efficiency and drug loading 
concentration of capecitabine/PAMAM dendrimer 
Formulation 
(cap/den) 
Drug loading 
concentration (%) 
Encapsulation 
efficiency (%) 
F1(5:1) 57.4 28.73 
F2 (5:2) 62.5 24.43 
F3 (5:3) 68.2 19.1 
F4 (5:4) 72.3 16.46 
F5 (5:5) 78.6 13.34 
 
 
2.2. Tumor type 
Azoxymethane changed normal colon tissue and 
induced colon adenocarcinoma in NMRI mice (Figure 
2e). In this study, we observed normal mucosa (Figure 
2a) adenovillus polyp (Figure 2b) dysplastic polyp 
(Figure 2c) dysplastic gland (Figure 2d) and invasive 
adenocarcinoma (Figure 2e) in groups under 
carcinogenic administration. 
In the capecitabine group, we saw decrease tumor 
size and tumor tissue was better than positive control. 
(Figure 2f). In PAMAM dendrimer group we saw 
invasive adenocarcinoma-like positive control group 
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(Figure 2g). In the animals that received capecitabine-
dendrimer complex colon tissue was better than 
positive control and capecitabine group (Figure 2h). 
 
 
 
Figure 2. Colorectal histological changes after H and E staining in different experimental groups*400 
a; vehicle control: normal colorectal histology* 400, b; positive control: received azoxymethane (10 mg/kg, i.p) for cancer induction (adenovillus 
polyp), c; positive control: received azoxymethane (10 mg/kg, i.p) for cancer induction (dysplastic polyp), d; positive control: received azoxymethane 
(10 mg/kg, i.p) for cancer induction (dysplastic glands), e; positive control: received azoxymethane (10 mg/kg, i.p) for cancer induction(invasive 
adenocarcinoma), f; capecitabine: capecitabine-fed (700 mg/kg/daily, gavage) post cancer induction, g; PAMAM dendrimer: PAMAM dendrimer 
received post cancer induction, h; capecitabine conjugated PAMAM denrimer: capecitabine-PAMAM dendrimer complex received post cancer 
induction 
 
 
2.3. Effect of capecitabine and capecitabine-PAMAM 
dendrimer complex on tumor size 
Compared to vehicle control and positive control 
groups, animals received capecitabine-PAMAM 
dendrimer complex had smaller colon lesion (P<0.05). 
Administration of capecitabine alone did not 
significantly reduce adenocarcinoma growth; whereas 
capecitabine-PAMAM dendrimer complex significantly 
reduced adenocarcinoma growth. Capecitabine alone 
decreased adenocarcinoma volume per mouse to 15.9 
mm3, versus 17.6 mm3in AOM group (Figure 3). 
However, capecitabine-PAMAM dendrimer complex 
resulted in a marked and significant reduction in 
adenoma volume per mouse to 6.8 mm3. We observed a 
decrease in tumor size in animals treated with 
capecitabine and capecitabine PAMAM dendrimer 
complex compared to positive control. 
RBCs decreased in capecitabine group compared 
with others (Figure 5). In this study, we showed that 
neoadjuvant chemotherapy with capecitabine could 
decrease RBC and platelet counts in male inbred NMRI 
albino mice, but complex form with PAMAM dendrimer 
had fewer effects on blood cell lines. 
 
 
Figure 3. Tumor size in different experimental groups 
 *P<0.05 compared to positive control group; ≠ P<0.05 compared to capecitabine group 
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2.4. Blood cell study 
Platelet counts were significantly higher in control 
than capecitabine received animals (Figure 4).  
 
 
 
Figure 4. Platelet counts in different experimental groups 
* P<0.05 compared to positive control group; ≠ P<0.05 compared 
to capecitabine group 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. RBC count in different experimental groups. 
* P<0.05 compared to Positive control group; ≠ P<0.05 compared 
to capecitabine group 
 
2.5. Liver enzymes 
Capecitabine received animals (group 3) showed 
significant elevation of AST and ALT compared to the 
control animals (Figure 6 and 7), but in azoxymethane 
received animals (group 2), AST and ALT levels 
showed no significant changes compared to the control 
group. ALT and AST levels strikingly decreased in 
capecitabine-PAMAM dendrimer complex received 
animals compared to the capecitabine group (P<0.001) 
but when compared with group 1 and 2, no significant 
difference was seen. PAMAM dendrimer received 
animals (group 4), showed statistically lowered ALT 
and AST level compared to group 3 (P<0.001), however 
in group 4, a significant difference in AST level was 
noticed compared with control animals. 
 
 
Figure 6. AST level in different experimental groups 
*P<0.001 compared to vehicle control groups; ≠ P<0.001 
compared to capecitabine group 
 
 
 
Figure 7. ALT level in different experimental groups 
* P<0.001 compared to vehicle control group; ≠ P<.001 compared 
with capecitabine group 
 
Discussion 
 
One of the major goals of the cancer chemotherapy is 
to decrease chemotherapeutic agents’ side effects in the 
clinical atmosphere. In the current study, first we made a 
colon cancer model by azoxymethane, a carcinogenic 
agent, administration, and then investigated if we could 
use capecitabine-PAMAM dendrimer complex to 
improve drug delivery and attenuate high 
chemotherapeutics’ side effects. Predictably, we noticed 
that the capecitabine complex form could fairly reduce 
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side effects in neoadjuvant chemotherapy and decrease 
tumor size. 
In this study, the effects of capecitabine/dendrimer ratio 
on encapsulation efficiency and drug Loading 
concentration was demonstrated. Increasing PAMAM 
dendrimer concentration during encapsulation process 
provoked more protonated form while boosting surface 
charge led to stronger electrostatic interaction between 
capecitabine and PAMAM dendrimer. Encapsulation 
efficiency of capecitabine increased with higher 
PAMAM dendrimer concentration. Capecitabine drug 
loading concentration was also increased when 
PAMAM dendrimer concentration boosted. Reversed 
correlation was seen between encapsulation efficiency 
and capecitabine loading concentration. When 
capecitabine loading concentration increased, more 
capecitabine molecules electrostatically adsorbed onto 
the surface of PAMAM dendrimer and in turn PAMAM 
dendrimer separation was easily done after 
centrifugation. 
Azoxymethane administration led to carcinogenicity 
as expected. After injection, it traveled to the liver and 
colon via the arterial system and induced colonic tumors 
when reached to the epithelium from the circulatory 
system (46-48). A greater percentage of invasive colonic 
adenocarcinoma has also been induced by multiple 
weekly injections (49,50). In this study, azoxymethane 
changed normal colon tissue and induced colon 
adenocarcinoma in NMRI mice. We observed normal 
mucosa, adenovillus polyp, dysplastic polyp, dysplastic 
gland and invasive adenocarcinoma in groups under 
carcinogenic administration. 
In capecitabine group tumor size and lesion 
development were lower than positive control. In 
PAMAM dendrimer group, invasive adenocarcinoma 
has been induced like the positive control group. In the 
animals received capecitabine/dendrimer complex, colon 
tissue changes were significantly improved compared 
with positive control and capecitabine group. Compared 
to vehicle control and positive control groups, animals 
received capecitabine-PAMAM dendrimer complex had 
smaller colon lesion. Administration of capecitabine did 
not significantly reduce adenocarcinoma growth; 
whereas capecitabine-PAMAM dendrimer complex 
significantly reduced it. We observed a decrease in 
tumor size in animals treated with capecitabine and 
capecitabine PAMAM dendrimer complex compared to 
positive control. In capecitabine group, the drug 
distributed post administration in the whole body, and 
consequently its tumor accumulation rate together with 
the drug side effects would be reduced. Capecitabine 
could modestly reduce tumor size compared with a 
positive control group which may be due to the 
frequency of chemotherapy treatment. Increasing 
chemotherapy cycles may significantly reduce tumor 
size in capecitabine group compared to positive control. 
Decreased tumor size in animals received 
capecitabine-PAMAM dendrimer complex was also 
significant. EPR effect caused capecitabine-PAMAM 
dendrimer complex accumulation in tumoral tissues and 
decreased tumor size compared to other experimental 
groups. 
In this study, we showed that neoadjuvant 
chemotherapy with capecitabine could decrease RBC 
and platelet counts in male inbred NMRI albino mice, 
but complex form with PAMAM dendrimer had fewer 
side effects on blood cell lines. Capecitabine adverse 
decremental response on blood cell lines may be due to 
bone marrow depression. Capecitabine PAMAM 
dendrimer complex provoked low distribution of free 
capecitabine in non-tumoral tissues and furnished 
protective effects on blood cell lines. 
We showed that capecitabine could increase AST and 
ALT level in NMRI mice compared to positive control 
groups, but capecitabine PAMAM dendrimer complex 
had a weaker side effect on liver enzymes compared to 
control and capecitabine groups. PAMAM dendrimer 
enhanced capecitabine accumulation at the tumor site 
and decreased capecitabine untoward sequel on liver 
enzymes. 
We showed that capecitabine-PAMAM dendrimer 
complex could decrease tumor size and adverse side 
effects on healthy tissues compared to free capecitabine 
in NMRI mice colorectal cancer model. 
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